Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis

References

• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130(23):2475–2483. DOI:https://doi.org/10.1182/blood-2017-06-782037.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599–1613. DOI:https://doi.org/10.1002/ajh.26008.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Maffioli M. The role of JAK2 inhibitors in MPNs 7 years after approval. Blood. 2018;131(22):2426–2435. DOI:https://doi.org/10.1182/blood-2018-01-791491.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821–829. DOI:https://doi.org/10.3324/haematol.2016.143644.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701–1707. DOI:https://doi.org/10.1038/leu.2016.148.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889–1897. DOI:https://doi.org/10.1182/blood-2017-05-785790.
   PubMed Web of Science ®Google Scholar
• Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017;176(1):76–85. DOI:https://doi.org/10.1111/bjh.14382.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 in hibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127. DOI:https://doi.org/10.1056/NEJMoa1002028.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. DOI:https://doi.org/10.1056/NEJMoa1110556.
   PubMed Web of Science ®Google Scholar
• Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neodelimplasms. Cancer Res. 2015;75(11):2187–2199. DOI:https://doi.org/10.1158/0008-5472.CAN-14-3198.
   PubMed Web of Science ®Google Scholar
• Keohane C, Kordasti S, Seidl T, et al. JAK inhibition induces silencing of T helper cytokine secretion and a profound reduction in T regulatory cells. Br J Haematol. 2015;171(1):60–73. DOI:https://doi.org/10.1111/bjh.13519.
   PubMed Web of Science ®Google Scholar
• Rumi E, Sant'Antonio E, Cavalloni C, et al. Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematol Oncol. 2020;38(4):554–559. DOI:https://doi.org/10.1002/hon.2769.
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202. DOI:https://doi.org/10.1182/blood-2013-03-484642.
   PubMed Web of Science ®Google Scholar
• Hanna RM, Khalid M, El-Nour LA, et al. Frequent Klebsiella pneumoniae urinary tract infections in a patient treated with ruxolitinib. Antibiotics. 2019;8(3):150.
   Google Scholar
• Khalid F, Damlaj M, AlZahrani M, et al. Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: case series and literature review. Hematol Oncol Stem Cell Ther. 2020. DOI:https://doi.org/10.1016/j.hemonc.2020.02.003.
   Google Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99. DOI:https://doi.org/10.1016/S1470-2045(16)30558-7.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. DOI:https://doi.org/10.1056/NEJMoa1409002.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97(9):1591–1600. DOI:https://doi.org/10.1007/s00277-018-3365-y.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55. DOI:https://doi.org/10.1186/s13045-017-0417-z.
   PubMedGoogle Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. DOI:https://doi.org/10.1056/NEJMoa1110557.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047–4053. DOI:https://doi.org/10.1182/blood-2013-02-485888.
   PubMed Web of Science ®Google Scholar
• Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis B virus DNA during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med. 2016;55(10):1341–1344. DOI:https://doi.org/10.2169/internalmedicine.55.5529.
   PubMed Web of Science ®Google Scholar
• Kusano Y, Terui Y, Ueda K, et al. Epstein-Barr virus gastric ulcer associated with ruxolitinib. Ann Hematol. 2016;95(10):1741–1742. DOI:https://doi.org/10.1007/s00277-016-2748-1.
   PubMed Web of Science ®Google Scholar
• Prakash K, Richman D. A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib. BMC Infect Dis. 2019;19(1):287. DOI:https://doi.org/10.1186/s12879-019-3922-6.
   PubMedGoogle Scholar
• Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347. DOI:https://doi.org/10.1002/ajh.24976.
   PubMed Web of Science ®Google Scholar
• Hirai N, Kasahara K, Yoshihara S, et al. Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-ruxolitinib-associated disseminated tuberculosis: a case report and literature review. IDCases. 2020;21:e00892. DOI:https://doi.org/10.1016/j.idcr.2020.e00892.
   PubMed Web of Science ®Google Scholar
• Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059–20063. DOI:https://doi.org/10.1074/jbc.R700016200.
   PubMed Web of Science ®Google Scholar